Mavrilimumab receives orphan designation in the US for the treatment of Giant Cell Arteritis

Mavrilimumab is an investigational fully-human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα). It is also being investigated in rheumatoid arthritis and severe COVID-19 pneumonia.

Biospace Inc.